Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11

This study has been completed.
Information provided by (Responsible Party):
University of Chicago Identifier:
First received: September 20, 1999
Last updated: July 23, 2013
Last verified: July 2013

The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To examine sevoflurane versus isoflurane inhalation at subanesthetic concentrations on mood, pain, and psychomotor performance.

Condition Intervention
Opioid-Related Disorders
Substance-Related Disorders
Drug: 15 % Nitrous oxide
Drug: 0.3 % Sevoflurane
Drug: 30% Nitrous oxide
Drug: 0.6% Sevoflurane
Other: Placebo

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations

Resource links provided by NLM:

Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • Pain intensity [ Time Frame: 30 min of inhalation ] [ Designated as safety issue: No ]
    Subjects underwent a 3 min cold immersion test at 30 min of inhalation and then provided response to pain intensity questionnaire

  • Psychomotor performance [ Time Frame: Baseline, 5 min of inhalation; 5, 30, 60 minutes recovery ] [ Designated as safety issue: No ]
    Subjects underwent psychomotor testing at baseline, during inhalation, and during recovery post inhalation

  • Cognitive performance [ Time Frame: Baseline, every 5 min during inhalation, 5, 30, & 60 min during recovery ] [ Designated as safety issue: No ]
    Subject underwent memory, sedation, visual analog, and drug effects testing

Enrollment: 12
Study Start Date: August 1996
Study Completion Date: November 1997
Primary Completion Date: November 1997 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Subject inhales no drug (100% oxygen)
Other: Placebo
Active Comparator: 0.3% sevoflurane Drug: 0.3 % Sevoflurane
Active Comparator: 0.6% sevoflurane Drug: 0.6% Sevoflurane
Active Comparator: 15% Nitrous oxide Drug: 15 % Nitrous oxide
Active Comparator: 30% Nitrous oxide Drug: 30% Nitrous oxide


Ages Eligible for Study:   21 Years to 39 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000259

United States, Illinois
University of Chicago, Anesthesia & Critical Care
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
Principal Investigator: James Zacny, Ph.D. University of Chicago
  More Information

No publications provided

Responsible Party: University of Chicago Identifier: NCT00000259     History of Changes
Other Study ID Numbers: NIDA-08391-11, R01DA008391, R01-08391-11
Study First Received: September 20, 1999
Last Updated: July 23, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Pathologic Processes
Nitrous Oxide
Analgesics, Non-Narcotic
Anesthetics, General
Anesthetics, Inhalation
Central Nervous System Agents
Central Nervous System Depressants
Hematologic Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Sensory System Agents
Therapeutic Uses processed this record on November 20, 2014